Litcius/Paper detail

Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses

Valeria Napolitano, Agnieszka Dąbrowska, Kenji Schorpp, André Mourão, Emilia Barreto-Durán, Małgorzata Benedyk, Paweł Botwina, Stefanie Brandner, Mark J. Bostock, Yuliya Chykunova, Anna Czarna, Grzegorz Dubin, Tony Fröhlich, Michael Hölscher, Malwina Jędrysik, Alex Matsuda, Katarzyna Owczarek, Magdalena Pachota, Oliver Plettenburg, Jan Potempa, Ina Rothenaigner, Florian Schlauderer, Klaudia Słysz, Artur Szczepański, Kristin Greve-Isdahl Mohn, Bjørn Blomberg, Michael Sattler, Kamyar Hadian, Grzegorz M. Popowicz, Krzysztof Pyrć

2022Cell chemical biology62 citationsDOIOpen Access PDF

Topics & Concepts

AcriflavineDrugIn vivoVirologyPandemicTitrationEx vivoOutbreakBiologyChemistryPharmacologyMicrobiologyCoronavirus disease 2019 (COVID-19)MedicineDiseaseGeneticsInfectious disease (medical specialty)PathologyInorganic chemistrySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies
Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses | Litcius